MAD-ID The Antimicrobial Stewardship Meeting®️
@mad_id_asp
Making a Difference in Infectious Diseases • a non-profit group for infectious diseases & stewardship education • #MADID2025
ID: 973604885735276545
https://mad-id.org 13-03-2018 17:01:08
1,1K Tweet
5,5K Followers
1,1K Following
Great start to Friday at #MADID2025 listening to Pharmacy Practice News board member Jason Pogue, PharmD, of U-M College of Pharmacy talk in the PK/PD session. Check back on our website to hear more coming soon! idse.net
Did you miss Dr. Ashlan J. Kunz Coyne's #MADID2025 talk about new antibiotics? She sat down with IDSE to give us some highlights. Check out the full video on our website and a part 2 coming soon! idse.net/a/uS0BAA/t University of Kentucky College of Pharmacy MAD-ID The Antimicrobial Stewardship Meeting®️ #pharmacy
At #MADID2025, Dr. Rachel Kenney, from Henry Ford Hospital, highlighted evolving C diff management, from fidaxomicin as first-line therapy to new FDA-approved microbiome therapies like Vowst & Rebyota. MAD-ID The Antimicrobial Stewardship Meeting®️ 💊 Listen here: contagionlive.com/view/advancing…
At #MADID2025, Dakota Rorie, PharmD from Medical University of South Carolina, found fidaxomicin use for C. difficile stayed nearly flat post-guideline update, 48% to 49% for initial episodes. MAD-ID The Antimicrobial Stewardship Meeting®️ Listen to our interview here: contagionlive.com/view/fidaxomic…
🎥 At #MADID2025, Dr. Jiye Park from Massachusetts General Hospital shared data showing no added benefit from extending oral vancomycin after systemic antibiotics for CDI prophylaxis. MAD-ID The Antimicrobial Stewardship Meeting®️ Listen to more of the results here: contagionlive.com/view/oral-vanc…
Curious about new antibiotics? Check out the highlights of Dr. Ashlan J. Kunz Coyne's #MADID2025 talk on our website! idse.net/a/uS0BAA/t University of Kentucky College of Pharmacy MAD-ID The Antimicrobial Stewardship Meeting®️ #pharmacy
Dr. Ashlan J. Kunz Coyne's gives highlights from her talk on new antibiotics during #MADID2025. Check it out on our website! idse.net/a/uS0BAA/t #pharmacy University of Kentucky College of Pharmacy MAD-ID The Antimicrobial Stewardship Meeting®️
🎥 At #MADID2025, Dr. Kimberly Leuthner, PharmD FIDSA, from UMC, presented data showing no significant difference in outcomes between TMP/SMX and minocycline for Stenotrophomonas maltophilia pneumonia. MAD-ID The Antimicrobial Stewardship Meeting®️ Listen here: contagionlive.com/view/trimethop…
Another great talk from #MADID2025 : Advances in Diagnostic and Laboratory Science with Romney Humphries MAD-ID The Antimicrobial Stewardship Meeting®️ #microbiology
#MADID2025 has wrapped up in Orlando, but we’re continuing our coverage this week. Look out for new interviews, research highlights, and expert insights all week! MAD-ID The Antimicrobial Stewardship Meeting®️ 🎥 Stay tuned for Dr. Tiffany Lee, PharmD, interview this week! Coverage: contagionlive.com/conference/mad…
Gram-positive bloodstream Infections #MADID2025 Erin McCreary MAD-ID The Antimicrobial Stewardship Meeting®️
At #MADID2025, Dr. Logan Brock presented that routine fungal blood cultures during sepsis evaluations may offer limited diagnostic value; a more targeted approach may be appropriate. MAD-ID The Antimicrobial Stewardship Meeting®️ Listen here: contagionlive.com/view/rethinkin…
At #MADID2025, Dr's. Julia F. & Christina Lee from UNC Hospitals presented that immunocompromised patients on OPAT had a 27.1% 30-day readmission rate compared to 14.1% in non-immunocompromised patients. MAD-ID The Antimicrobial Stewardship Meeting®️ Listen here: contagionlive.com/view/immunocom…
🎥 At #MADID2025, Dr. William Mikesell from IU Health shared findings showing no significant difference in treatment failure between doxycycline (20%) and minocycline (16%) for bone & joint infections. MAD-ID The Antimicrobial Stewardship Meeting®️ Listen here: contagionlive.com/view/no-signif…
🎥 At #MADID2025, Dr. Jose Alexander from AdventHealth in Orlando, discussed data that ceftolozane/tazobactam showed 98% susceptibility against ESBL E. coli but only 76% for K. pneumoniae. MAD-ID The Antimicrobial Stewardship Meeting®️ Full interview: contagionlive.com/view/ceftoloza…
At #MADID2025, Dr. Alyssa Cox, PharmD, presented data showing fidaxomicin reduced 90-day C. difficile recurrence rates to 7.9% vs. 19% with vancomycin, a 68.3% lower risk in high-risk hospitalized patients. MAD-ID The Antimicrobial Stewardship Meeting®️ Listen here: contagionlive.com/view/fidaxomic…
📣 Attention Program Directors! Sign up is OPEN! 🌟 MAD-ID is excited to spotlight your PGY2 ID pharmacy residency or ID pharmacy fellowship program in the upcoming academic year! 🎓 See eligibility criteria! Sign up and learn more here: forms.office.com/r/86HfX98XqT ACCP INFD PRN
A critical #Global issue that impacts everyone! Learn more here in my Contagion Live #podcast with #pharmacist expert, Dr. Timothy Gauthier MAD-ID The Antimicrobial Stewardship Meeting®️ #AMR Debbie Goff #ScienceCommunication #scicomm #AntimicrobialResistanceAwareness
